BIOMAT Database Logo BIOMAT Database Logo

Immunotropic effects of potentiated antibodies to human interferon-gamma. 2003

E Yu Sherstoboev, and N M Masnaya, and A A Churin, and O S Borsuk, and A V Martyushev, and S A Sergeeva, and O I Epstein, and A M Dygai, and E D Goldberg
Institute of Pharmacology, Tomsk Research Center, Siberian Division of the Russian Academy of Medical Sciences.

We studied immunotropic properties of antibodies to human interferon-gamma in homeopathic doses. The effects of these antibodies on the ratio between the counts of T helper (CD4+) and T suppressor cells (CD8+), production of interleukin-1 and interleukin-2, and functional activity of natural killer cells were evaluated. Potentiated antibodies slightly decreased the number of CD8+ cells in the spleen of experimental animals. After the addition to cultured human mononuclear cells the preparation produced a moderate comitogenic effect, stimulated proliferation of T and B lymphocytes, increased spontaneous and induced production of interleukin-1, and enhanced functional activity of natural killer cells (under certain conditions).

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D008297 Male Males
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

E Yu Sherstoboev, and N M Masnaya, and A A Churin, and O S Borsuk, and A V Martyushev, and S A Sergeeva, and O I Epstein, and A M Dygai, and E D Goldberg
[Neutralizing antibodies to human gamma-interferon].
January 1985, Voprosy virusologii,
E Yu Sherstoboev, and N M Masnaya, and A A Churin, and O S Borsuk, and A V Martyushev, and S A Sergeeva, and O I Epstein, and A M Dygai, and E D Goldberg
[Monoclonal antibodies to natural human gamma-type interferon].
January 1991, Voprosy virusologii,
E Yu Sherstoboev, and N M Masnaya, and A A Churin, and O S Borsuk, and A V Martyushev, and S A Sergeeva, and O I Epstein, and A M Dygai, and E D Goldberg
Characterization of mouse monoclonal antibodies to human interferon-gamma.
January 1988, Microbiology and immunology,
E Yu Sherstoboev, and N M Masnaya, and A A Churin, and O S Borsuk, and A V Martyushev, and S A Sergeeva, and O I Epstein, and A M Dygai, and E D Goldberg
Monoclonal antibodies to human interferon-gamma. II: Antibodies with neutralizing activity.
April 1987, Hybridoma,
E Yu Sherstoboev, and N M Masnaya, and A A Churin, and O S Borsuk, and A V Martyushev, and S A Sergeeva, and O I Epstein, and A M Dygai, and E D Goldberg
Natural antibodies to interferon-gamma.
January 1997, Biotherapy (Dordrecht, Netherlands),
E Yu Sherstoboev, and N M Masnaya, and A A Churin, and O S Borsuk, and A V Martyushev, and S A Sergeeva, and O I Epstein, and A M Dygai, and E D Goldberg
Cytogenetic effects of antibodies to gamma-interferon in ultralow doses.
January 2003, Bulletin of experimental biology and medicine,
E Yu Sherstoboev, and N M Masnaya, and A A Churin, and O S Borsuk, and A V Martyushev, and S A Sergeeva, and O I Epstein, and A M Dygai, and E D Goldberg
Monoclonal antibodies to human interferon-gamma. I. Antibodies to a synthetic carboxyl-terminal peptide.
June 1985, Journal of immunological methods,
E Yu Sherstoboev, and N M Masnaya, and A A Churin, and O S Borsuk, and A V Martyushev, and S A Sergeeva, and O I Epstein, and A M Dygai, and E D Goldberg
Antibodies to synthetic polypeptides corresponding to hydrophilic regions of human interferon gamma.
August 1985, Molecular immunology,
E Yu Sherstoboev, and N M Masnaya, and A A Churin, and O S Borsuk, and A V Martyushev, and S A Sergeeva, and O I Epstein, and A M Dygai, and E D Goldberg
Detection of hybridomas secreting monoclonal antibodies to human gamma interferon using a rapid screening technique and specificity of certain monoclonal antibodies to gamma interferon.
January 1984, Journal of interferon research,
E Yu Sherstoboev, and N M Masnaya, and A A Churin, and O S Borsuk, and A V Martyushev, and S A Sergeeva, and O I Epstein, and A M Dygai, and E D Goldberg
Monoclonal antibodies to human interferon-gamma: production, affinity purification and radioimmunoassay.
January 1983, The EMBO journal,
Copied contents to your clipboard!